APRIL expression was significantly higher in the responder's group (expected to have increased local androgen levels), while it was not changed in the non-responders, verifying our hypothesis on testosterone-control of APRIL in breast cancer. The gene discussed is TNFSF13; the disease is breast carcinoma.